Based on the concentration of circulating SOX2 antibodies, the investigators were able to discriminate between breast cancer patients and healthy controls (P < 0.001) and between breast cancer patients and those with benign breast disease (P < 0.001). Here, SOX2 is linked to breast fibrocystic disease.